NanoViricides, Inc. NEW (NNVC): Price and Financial Metrics


NanoViricides, Inc. NEW (NNVC): $1.73

0.05 (+2.98%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add NNVC to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

NNVC Stock Price Chart Interactive Chart >

Price chart for NNVC

NNVC Price/Volume Stats

Current price $1.73 52-week high $5.56
Prev. close $1.68 52-week low $1.04
Day low $1.65 Volume 28,000
Day high $1.78 Avg. volume 239,653
50-day MA $2.22 Dividend yield N/A
200-day MA $2.23 Market Cap 19.99M

NanoViricides, Inc. NEW (NNVC) Company Bio


NanoViricides, Inc. is a biopharmaceutical company. The Company researches treatments for viruses such as AIDS/HIV, Hepatitis C, influenza, and Asian bird flu.


NNVC Latest News Stream


Event/Time News Detail
Loading, please wait...

NNVC Latest Social Stream


Loading social stream, please wait...

View Full NNVC Social Stream

Latest NNVC News From Around the Web

Below are the latest news stories about NANOVIRICIDES INC that investors may wish to consider to help them evaluate NNVC as an investment opportunity.

Monkeypox Is Popping Up In Places It Shouldn’t But NanoViricides Says It May Have A Solution

Benzinga - Rachel Green

Yahoo | August 10, 2022

NanoViricides Provides Additional Details on Its Rapid Monkeypox Drug Strategy

NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a global leader in the development of highly effective antiviral therapies based on a novel nanomedicines platform, provides further details on its rapid drug development strategy for Monkeypox virus.

Yahoo | August 9, 2022

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday

Good morning!

William White on InvestorPlace | August 4, 2022

NanoViricides shares soar 41% after announcing plans to develop a monkeypox treatment

Shares of NanoViricides Inc. jumped 41.8% in premarket trading on Thursday after the company said it began developing a monkeypox treatment. There are currently no approved or authorized therapies for monkeypox, though the Food and Drug Administration said last month that it's allowing prescriptions of the antiviral Tpoxx through a compassionate-use pathway. Tpoxx is made by Siga Technologies Inc. . NanoViricides' stock has slid 33.8% so far this year, while the broader S&P 500 is down 12.8%.

Yahoo | August 4, 2022

NanoViricides Reports That It Has Begun Drug Development to Combat Monkeypox Virus

NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a global leader in the development of highly effective antiviral therapies based on a novel nanomedicines platform, reports that it has begun drug development to combat the monkeypox virus.

Yahoo | August 4, 2022

Read More 'NNVC' Stories Here

NNVC Price Returns

1-mo -22.42%
3-mo -8.47%
6-mo -19.16%
1-year -60.68%
3-year -13.50%
5-year -92.35%
YTD -53.49%
2021 29.62%
2020 14.34%
2019 -37.25%
2018 -77.27%
2017 -17.76%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.662 seconds.